Sickle Cell Treatment Enters Phase 3 Clinical Trial

Published July 23, 2010

Sickle cell treatment enters Phase 3 clinical trial
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute (LA BioMed) has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.
Read more on PhysOrg

Achillion sees promise in anti-HCV treatment
New Haven drug developer Achillion Pharmaceuticals Inc. is preparing clinical testing of a compound that it says could be a promising treatment with other drugs in its stable against the hepatitis C virus (HCV).
Read more on Hartford Business Journal